The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Peptide Therapeutics: Contract API Manufacturing Market, 2020 - 2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    285

  • View Count
    1450

Example Insights

Peptide-Therapeutics-Contract-API-Manufacturing-Market,2020-2030-Context Peptide-Therapeutics-Contract-API-Manufacturing-Market,2020-2030-Clinical-Research-Landscape Peptide Therapeutics: Contract API Manufacturing Market, 2020 - 2030 - List of Manufacturers
Peptide-Therapeutics-Contract-API-Manufacturing-Market,2020-2030-manufacturers-landscape Peptide Therapeutics: Contract API Manufacturing Market, 2020 - 2030 - Manufacturer Locations Peptide-Therapeutics-Contract-API-Manufacturing-Market,2020-2030-Recent-expansions
Peptide-Therapeutics-Contract-API-Manufacturing-Market,2020-2030-Capacity-analysis Peptide-Therapeutics-Contract-API-Manufacturing-Market,2020-2030-market-forecast
 

 

Overview

Since the establishment of the therapeutic relevance of insulin in the early 1920s, peptide therapeutics have come a long way. Presently, there are over 60 peptide-based drugs available in the market. Specifically, these products represent one of the earliest classes of biologics and have, so far, demonstrated significant potential in the treatment of a variety of metabolic and oncological disorders. Examples of popular, marketed therapeutic peptides include Victoza®, LUPRON DEPOT®, Zoladex®, Sandostatin® and Somatuline®. Further, according to experts, more than 600 pharmacological leads based on peptides are currently being investigated across various phases of development. Owing to their proven pharmacological value and favorable safety profiles, the demand for peptide drugs is on the rise. As a result, there is increasing interest in manufacturing solutions for large quantities of such molecules, often requiring complex manipulations of long macromolecular structures, chemical modifications and thorough purification, for both clinical and basic research applications.

Although a lot has been achieved in terms of improvements in peptide synthesis and purification methods, there are certain challenges, especially those related to large-scale manufacturing capabilities, which continue to plague drug developers in this domain. Additionally, there are certain technical complications related to the synthesis of complex, long chain macromolecules, which are known to compromise both product yield and purity. In order to optimize production processes and associated expenses, leverage superior expertise and infrastructure, and expedite time to market, many innovator companies have demonstrated the preference to work with specialty service providers. Presently, there are a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) that offer elaborate portfolios of services focused on peptide design, manufacturing and purification. Given the historical and prevalent trends in demand for peptide synthesis and purification services, several CMOs / CDMOs are actively expanding their capabilities and capacity to ensure consistent supply. We are led to believe that sponsor companies are likely to continue relying on contract manufacturing service providers over the coming decade. 

Scope of the Report

The “Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of therapeutic peptides. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract services for manufacturing of peptides, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location of CMO, number and location of their respective facilities, type of peptide synthesis method used, type of peptide modification services offered, peptide purification technology used, and regulatory accreditations / certifications.   
  • An analysis on the recent developments in the industry, highlighting collaborations, facility expansions, and upcoming peptide synthesis technologies within this domain. 
  • Informed estimates of the annual commercial and clinical demand for manufacturing peptides for therapeutic use, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A clinical trial analysis of completed, and active studies related to peptide therapeutics that are have been / being / likely to be conducted across various geographies, based on the trial registration year, trial phase, trial recruitment status, therapeutic areas type of sponsor / collaborator, geography and number of patients enrolled.
  • An estimate of the overall, installed capacity for manufacturing peptides, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available peptide production capacity across companies of different sizes (small, mid-sized, large and very large firms), scale of operation (clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific). 
  • A discussion on regulatory guidelines related to peptide manufacturing, highlighting key differences across various geographies, including the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.
  • Elaborate profiles of the key players that offer contract manufacturing services across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.  
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field; it includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics. 

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptide contract manufacturing market. Based on multiple parameters, such as projected growth of overall peptide-based products market, cost of goods sold and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] distribution scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] end user (small, mid-sized and large / very large), and [D] key geographical regions (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the peptide contract manufacturing market and its likely evolution in the short-mid-term and long term.

Chapter 3 provides a general introduction to peptides, including a brief overview of different peptide classes, popular methods used for peptide synthesis and modification. It also highlights the different purification strategies that are available in the market. The chapter includes information on the various applications of peptides. In addition, it features a brief overview of contract manufacturing and a detailed discussion on the need for outsourcing peptide manufacturing operations and its advantages. 

Chapter 4 features a detailed discussion on the regulatory landscape related to peptide contract manufacturers across various geographies, such as the US, Europe, Australia, China, India, Japan and South Korea. It also includes details related to the various challenges, related to regulatory scrutiny, faced by peptide manufacturers.

Chapter 5 provides an overview of the peptide contract manufacturing landscape. It includes information on close to 50 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the CMO, number and location of manufacturing facilities, type of peptide synthesis method used, type of peptide modification services offered, peptide purification technology used, and regulatory accreditations / certifications. In addition, the chapter provides details of service providers that offer custom peptide synthesis services.

Chapter 6 features detailed profiles of industry players that offer various contract manufacturing services in different geographies such as, North America, Europe and Asia Pacific, at different scales of operation. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.

Chapter 7 presents an analysis of the recent developments in the peptide contract manufacturing market. It provides an overview of other market trends, such as collaborations and facility expansions. In addition, it features a discussion on the key developments related to manufacturing process, such as use of single-use technologies, continuous manufacturing and introduction of green chemistry for peptide synthesis.

Chapter 8 presents a geographical clinical trial analysis of completed and active related to peptide therapeutics / drugs. For the purpose of this analysis, we considered those clinical studies that have been initiated since 2010 and analyzed them on the basis of various parameters, such as trial registration year, trial phase, trial recruitment status, therapeutic areas, type of sponsors / collaborators  and number of patients enrolled across different geographies.

Chapter 9 provides an overview of various recent developments that have been undertaken in different geographies namely, North America, Europe and Asia Pacific. Thus, depicting the emerging strength of the contract peptide manufacturers in different regions.

Chapter 10 features a detailed analysis of the annual commercial and clinical demand for peptide therapeutics / drugs, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 11 features an analysis of the overall, installed capacity for manufacturing peptide therapeutics / drugs based on data reported by industry stakeholders in the public domain; it highlights the distribution of available peptide production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).

Chapter 12 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by peptide therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.

Chapter 13 presents a detailed market forecast analysis, highlighting the likely growth of the peptide contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] distribution scale of operation (preclinical / clinical and commercial) [B] type of synthesis method used [C] end user (small, mid-sized and large / very large), and [D] key geographical regions (North America, Europe, Asia Pacific).

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of peptide contract manufacturing market, under a SWOT framework.

Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the peptide CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of peptide CMOs.

Chapter 16 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the peptide therapeutics contract manufacturing market.

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Peptides
3.2.1. Structure of Peptides
3.2.2. Major Classes of Peptides
3.2.3. Synthesis of Peptides

3.2.4. Modification of Peptides
3.2.4.1. N-terminal Modification
3.2.4.2. Internal Modification
3.2.4.3. C-terminal Modification
3.2.4.4. Other Modifications

3.2.5. Purification of Peptides
3.2.6. Applications of Peptides

3.3. Overview of Contract Manufacturing
3.3.1. Need for Outsourcing in the Peptide Industry
3.3.2. Key Considerations for Selecting a CMO Partner
3.3.3. Advantages of Outsourcing Manufacturing Services
3.3.4. Risks and Challenges Associated with Outsourcing Peptide Manufacturing Services

3.4. Future Perspectives

4. REGULATORY LANDSCAPE
4.1. Chapter Overview
4.2. Regulatory Scenario in North America
4.2.1. The US Scenario
4.2.1.1. Overview
4.2.1.2. General Guidelines

4.3. Regulatory Scenario in Europe
4.3.1. The European Scenario
4.3.1.1. Overview
4.3.1.2. General Guidelines

4.4. Regulatory Scenario in Asia Pacific
4.4.1. Overview
4.4.2. Australian Scenario
4.4.2.1. General Guidelines
4.4.3. Chinese Scenario
4.4.3.1. General Guidelines
4.4.4. Indian Scenario
4.4.4.1. General Guidelines
4.4.5. Japanese Scenario
4.4.5.1. General Guidelines
4.4.6. South Korean Scenario
4.4.6.1. General Guidelines

4.5. Challenges Associated with Peptide Manufacturing

5. COMPETITIVE LANDSCAPE
5.1 Chapter Overview
5.2 Contract Peptide API Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Facilities

5.2.6. Analysis by Peptide Synthesis Method Used
5.2.7. Analysis by Peptide Modification Services Offered
5.2.8. Analysis by Purification Technology Used
5.2.9. Analysis by Regulatory Accreditations / Certifications

6. COMPANY PROFILES
6.1 Chapter Overview
6.2. Contract Peptide API Manufacturers based in North America
6.2.1. AmbioPharm
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Facilities and Capabilities
6.2.1.4. Recent Development and Future Outlook

6.2.2. CPC Scientific
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Facilities and Capabilities
6.2.2.4. Recent Developments and Future Outlook

6.2.3. Creative Peptides
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Facilities and Capabilities
6.2.3.4. Recent Developments and Future Outlook

6.2.4. CSBio
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Facilities and Capabilities
6.2.4.4. Recent Developments and Future Outlook

6.3. Contract Peptide API Manufacturers based in Europe
6.3.1. Bachem
6.3.1.1. Recent Developments and Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Facilities and Capabilities
6.3.1.4. Recent Developments and Future Outlook

6.3.2. BCN Peptide
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Facilities and Capabilities
6.3.2.4. Recent Developments and Future Outlook

6.3.3. Corden Pharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Facilities and Capabilities
6.3.3.4. Recent Developments and Future Outlook

6.3.4. PolyPeptide
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Manufacturing Facilities and Capabilities
6.3.4.4. Recent Developments and Future Outlook

6.3.5. Senn Chemicals
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Manufacturing Facilities and Capabilities
6.3.5.4. Recent Developments and Future Outlook

6.4. Contract Peptide API Manufacturers based in Asia Pacific
6.4.1. Auspep
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Facilities and Capabilities
6.4.1.4. Recent Developments and Future Outlook

6.4.2. Chinese Peptide
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Facilities and Capabilities
6.4.2.4. Recent Developments and Future Outlook

6.4.3. Hybio Pharmaceutical
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Facilities and Capabilities
6.4.3.4. Recent Developments and Future Outlook

6.4.4. Peptide Institute
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Manufacturing Facilities and Capabilities
6.4.4.4. Recent Developments and Future Outlook

6.4.5. ScinoPharm
6.4.5.1. Company Overview
6.4.5.2. Service Portfolio
6.4.5.3. Manufacturing Facilities and Capabilities
6.4.5.4. Recent Developments and Future Outlook

7. RECENT DEVELOPMENTS
7.1. Chapter Overview
7.2. Partnerships Models
7.3. List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation (Deal Specific)
7.3.4. Analysis by Region

7.4. Expansion Models
7.5. List of Expansions
7.5.1. Analysis by Year of Expansion
7.5.2. Analysis by Type of Expansion
7.5.3. Analysis by Location of Expansion Project

7.6. Emerging Peptide Synthesis Technologies

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology

8.3 Peptide Therapeutics: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Phase
8.3.3. Analysis by Trial Recruitment Status
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Sponsor / Collaborator
8.3.6. Analysis by Geography
8.3.7. Geographical Analysis by Trial Recruitment Status
8.3.8. Geographical Analysis by Trial Phase

8.4. Peptide Therapeutics: Analysis of Enrolled Patient Population
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Recruitment Status and Therapeutic Area
8.4.3. Analysis by Trial Location
8.4.4. Analysis by Trial Recruitment Status and Location
8.4.5. Analysis of Active Trials by Trial Phase and Location

9. REGIONAL CAPABILITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Regional Capability Analysis: Contract Peptide API Manufacturers in North America
9.4. Regional Capability Analysis: Contract Peptide API Manufacturers in Europe
9.5. Regional Capability Analysis: Contract Peptide API Manufacturing in Asia Pacific and Rest of the World

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodologies
10.3. Peptide API Manufacturing: Overall Annual Demand
10.3.1. Analysis by Scale of Operation
10.3.2. Analysis by Geography

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodologies
11.3. Peptide API Manufacturing: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks

12. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1. Chapter Overview
12.2. Assumptions and Key Parameters
12.3. Peptide Therapeutics Contract API Manufacturing: Make versus Buy Decision Making
12.4. Conclusion

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology
13.3. Overall Contract Peptide API Manufacturing Market, 2020-2030
13.4. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.5. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Peptide Synthesis Method Used
13.6. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by End User

13.7. Contract Peptide API Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions
13.7.1. Contract Peptide API Manufacturing Market in North America, 2020-2030
13.7.1.1. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.7.1.2. Contract Peptide API Manufacturing Market in North America,2020-2030: Share of Mid-sized Companies
13.7.1.3. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
13.7.1.4. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.1.5. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
13.7.1.6. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Chemical Synthesis Methods
13.7.1.7. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Non-Chemical Synthesis Methods

13.7.2. Contract Peptide API Manufacturing Market in Europe, 2020-2030
13.7.2.1. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.7.2.2. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
13.7.2.4. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.7.2.5. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
13.7.2.6. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Chemical Synthesis Methods
13.7.2.7. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Non-Chemical Synthesis Methods

13.7.3. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030
13.7.3.1. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.2. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.3. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.4. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.5. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Scale Operations
13.7.3.6. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-
13.7.3.7. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of SWOT Factors
14.7. Concluding Remark

15. CONCLUSION
15.1. Chapter Overview
15.2. Key Takeaways

16. SURVEY INSIGHTS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

List Of Figures

Figure 3.1. Primary Structure of Peptides
Figure 3.2. Secondary Structure of Peptides
Figure 3.3. Tertiary Structure of Peptides
Figure 3.4. Quaternary Structure of Peptides
Figure 3.5. Peptide Synthesis Methods
Figure 3.6. Different Type of Peptide Modifications
Figure 3.7. Type of Third-Party Service Providers
Figure 4.1. Regulatory Landscape: Peptide Classification in the US
Figure 5.1. Contract Peptide API Manufacturers: Distribution by Year of Establishment
Figure 5.2. Contract Peptide API Manufacturers: Distribution by Company Size
Figure 5.3. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Figure 5.4. Contract Peptide API Manufacturers: Distribution by Location of Headquarters
Figure 5.5. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.6. Contract Peptide API Manufacturers: Distribution by Peptide Synthesis Method Used
Figure 5.7. Contract Peptide API Manufacturers: Distribution by Peptide Modification Services Offered
Figure 5.8. Contract Peptide API Manufacturers: Distribution by Purification Technology Used
Figure 5.9. Contract Peptide API Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 6.1. AmbioPharm: Service Portfolio
Figure 6.2. CPC Scientific: Service Portfolio
Figure 6.3. Creative Peptides: Service Portfolio
Figure 6.4. CSBio: Service Portfolio
Figure 6.5. Bachem: Service Portfolio
Figure 6.6. BCN Peptide: Service Portfolio
Figure 6.7. Corden Pharma: Service Portfolio
Figure 6.8. PolyPeptide: Service Portfolio
Figure 6.9. Senn Chemical: Service Portfolio
Figure 6.10. Auspep: Service Portfolio
Figure 6.11. Chinese Peptide: Service Portfolio
Figure 6.12. Hybio Pharmaceuticals: Service Portfolio
Figure 6.13. Peptide Institute: Service Portfolio
Figure 6.14. ScinoPharm: Service Portfolio
Figure 7.1. Recent Partnerships: Distribution by Year of Partnership
Figure 7.2. Recent Partnerships: Distribution by Type of Partnership
Figure 7.3. Recent Partnerships: Distribution by Scale of Operations
Figure 7.4. Recent Partnerships: Continent-Wise Distribution
Figure 7.5. Recent Partnerships: Country-Wise Distribution
Figure 7.6. Recent Expansions: Distribution by Year of Expansion
Figure 7.7. Recent Expansions: Distribution by Type of Expansion
Figure 7.8. Recent Expansions: Distribution by Location of Expansion Project
Figure 8.1. Clinical Trial Analysis: Distribution by Trial Registration Year, 2010-2019
Figure 8.2. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 8.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 8.5. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.6. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.7. Clinical Trial Analysis: Distribution by Geography
Figure 8.8. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 8.9. Clinical Trial Analysis: Geographical Distribution of Active Trials by Trial Phase
Figure 8.10. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 8.11. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Therapeutic Area
Figure 8.12. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Location
Figure 8.13. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Location
Figure 8.14. Clinical Trial Analysis: Distribution of Enrolled Patient Population of Active Trials by Trial Phase and Location
Figure 9.1. Regional Capability Analysis: North America
Figure 9.2. Regional Capability Analysis: Europe
Figure 9.3. Regional Capability Analysis: Asia Pacific and Rest of the World
Figure 10.1. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
Figure 10.2. Demand Analysis: Annual Demand for Clinical Scale of Operation
Figure 10.3. Demand Analysis: Annual Demand for Commercial Scale of Operation
Figure 10.4. Demand Analysis: Annual Demand in North America
Figure 10.5. Demand Analysis: Annual Demand in Europe
Figure 10.6. Demand Analysis: Annual Demand in Asia Pacific
Figure 11.1. Contract Peptide API Manufacturers: Installed Global Capacity
Figure 11.2. Contract Peptide API Manufacturers: Distribution by Company Size
Figure 11.3. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Figure 11.4. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facility
Figure 12.1. Make versus Buy Decision Making Framework
Figure 12.2. Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 13.1. Overall Contract Peptide API Manufacturing Market, 2020-2030 (USD Million)
Figure 13.2. Contract Peptide API Manufacturing Market: Distribution by Scale of Operation, 2020-2030 (USD Million)
Figure 13.3. Contract Peptide API Manufacturing Market: Distribution by Peptide Synthesis Methods Used, 2020-2030 (USD Million)
Figure 13.4. Contract Peptide API Manufacturing Market: Distribution by Type of End User, 2020-2030 (USD Million)
Figure 13.5. Contract Peptide API Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030 (USD Million)
Figure 13.5. Contract Peptide API Manufacturing Market in North America, 2020-2030 (USD Million)
Figure 13.6. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Million)
Figure 13.7. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Million)
Figure 13.8. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Million)
Figure 13.9. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Figure 13.10. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Million)
Figure 13.11. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Figure 13.12. Contract Peptide API Manufacturing Market in North America, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Figure 13.13. Contract Peptide API Manufacturing Market in Europe, 2020-2030 (USD Million)
Figure 13.14. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Million)
Figure 13.15. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Million)
Figure 13.16. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Million)
Figure 13.17. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Figure 13.18. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Million)
Figure 13.19. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Figure 13.20. Contract Peptide API Manufacturing Market in Europe, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Figure 13.21. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030 (USD Million)
Figure 13.22. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies (USD Million)
Figure 13.23. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies (USD Million)
Figure 13.24. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies (USD Million)
Figure 13.25. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Figure 13.26. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations (USD Million)
Figure 13.27. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Figure 13.28. Contract Peptide API Manufacturing Market in Asia Pacific, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Figure 14.1. Contract Peptide API Manufacturing: SWOT Analysis
Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1. Comparison of Various Peptide Synthesis Methods
Table 3.2. Chromatographic Techniques
Table 5.1. List of Contract Peptide API Manufacturers
Table 5.2. Contract Peptide API Manufacturers: Information on Scale of Operation
Table 5.3. Contract Peptide API Manufacturers: Information on Peptide Synthesis Methods Used
Table 5.3. Contract Peptide API Manufacturers: Information on Peptide Modification Services Offered
Table 5.4. Contract Peptide API Manufacturers: Information on Purification Technology Used
Table 5.5. Contract Peptide API Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1. AmbioPharm: Company Overview
Table 6.2. AmbioPharm: Overview of Manufacturing Capabilities
Table 6.3. AmbioPharm: Recent developments and Future Outlook
Table 6.4. CPC Scientific: Company Overview
Table 6.5. CPC Scientific: Overview of Manufacturing Capabilities
Table 6.6. CPC Scientific: Recent developments and Future Outlook
Table 6.7. Creative Peptides: Company Overview
Table 6.8. Creative Peptides: Overview of Manufacturing Capabilities
Table 6.9. Creative Peptides: Recent developments and Future Outlook
Table 6.10. CSBio: Company Overview
Table 6.11. CSBio: Overview of Manufacturing Capabilities
Table 6.12. CSBio: Recent developments and Future Outlook
Table 6.13. Bachem: Company Overview
Table 6.14. Bachem: Overview of Manufacturing Capabilities
Table 6.15. Bachem: Recent developments and Future Outlook
Table 6.16. BCN Peptide: Company Overview
Table 6.17. BCN Peptide: Overview of Manufacturing Capabilities
Table 6.18. BCN Peptide: Recent developments and Future Outlook
Table 6.19. Corden Pharma: Company Overview
Table 6.20. Corden Pharma: Overview of Manufacturing Capabilities
Table 6.21. Corden Pharma: Recent developments and Future Outlook
Table 6.22. PolyPeptide: Company Overview
Table 6.23. PolyPeptide: Overview of Manufacturing Capabilities
Table 6.24. PolyPeptide: Recent developments and Future Outlook
Table 6.25. Senn Chemicals: Company Overview
Table 6.26. Senn Chemicals: Overview of Manufacturing Capabilities
Table 6.27. Senn Chemical: Recent developments and Future Outlook
Table 6.28. Auspep: Company Overview
Table 6.29. Auspep: Overview of Manufacturing Capabilities
Table 6.30. Auspep: Recent developments and Future Outlook
Table 6.31. Chinese Peptide: Company Overview
Table 6.32. Chinese Peptide: Overview of Manufacturing Capabilities
Table 6.33. Chinese Peptide: Recent developments and Future Outlook
Table 6.34. Hybio Pharmaceuticals: Company Overview
Table 6.35. Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
Table 6.36. Hybio Pharmaceuticals: Recent developments and Future Outlook
Table 6.37. Peptide Institute: Company Overview
Table 6.38. Peptide Institute: Overview of Manufacturing Capabilities
Table 6.39. Peptide Institute: Recent developments and Future Outlook
Table 6.40. ScinoPharm: Company Overview
Table 6.41. ScinoPharm: Overview of Manufacturing Capabilities
Table 6.42. ScinoPharm: Recent developments and Future Outlook
Table 7.1. Contract Peptide API Manufacturers: List of Partnerships, 2014-2020
Table 7.2. Contract Peptide API Manufacturers: List of Recent Expansions, 2014-2020
Table 7.3. Contract Peptide API Manufacturers: List of Emerging Peptide Synthesis / Manufacturing Technologies
Table 12.1. Parameters to Assess Complexity of Outsourcing Manufacturing Operations
Table 12.2. Contract Peptide API Manufacturing: Make versus Buy Decision Making
Table 17.1. Contract Peptide API Manufacturers: Distribution by Year of Establishment
Table 17.2. Contract Peptide API Manufacturers: Distribution by Company Size
Table 17.3. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Table 17.4. Contract Peptide API Manufacturers: Distribution by Location of Headquarters
Table 17.5. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facilities
Table 17.6. Contract Peptide API Manufacturers: Distribution by Type of Peptide Synthesis Methods Used
Table 17.7. Contract Peptide API Manufacturers: Distribution by Type of Peptide Modification Services Offered
Table 17.8. Contract Peptide API Manufacturers: Distribution by Type of Purification Technology Used
Table 17.9. Contract Peptide API Manufacturers: Distribution by Regulatory Accreditations / Certifications
Table 17.10 Partnerships: Distribution by Year of Partnerships
Table 17.11. Partnerships: Distribution by Type of Partnerships
Table 17.12. Partnerships: Distribution by Scale of Operations
Table 17.13. Partnerships: Country-Wise Distribution
Table 17.14. Partnerships: Continent-Wise Distribution
Table 17.15. Recent Expansions: Distribution by Year of Expansion
Table 17.16. Recent Expansions: Distribution by Type of Expansion
Table 17.17. Recent Expansions: Distribution by Location of Expansion Project
Table 17.18. Clinical Trial Analysis: Distribution by Trial Registration Year, Since-2010
Table 17.19. Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 17.20. Clinical Trial Analysis: Distribution by Trial Phase
Table 17.21. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 17.22. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.23. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.24. Clinical Trial Analysis: Distribution by Geography
Table 17.25. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 17.26. Clinical Trial Analysis: Geographical Distribution of Active Trials by Trial Phase
Table 17.27. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 17.28. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 17.29. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Therapeutic Area and Trial Recruitment Status
Table 17.30. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Recruitment Status
Table 17.31. Clinical Trial Analysis: Distribution of Enrolled Patient Population of Active Trials by Trial Phase and Location
Table 17.32. Regional Capability Analysis in North America
Table 17.33. Regional Capability Analysis in Europe
Table 17.34. Regional Capability Analysis in Asia Pacific
Table 17.35. Demand Analysis: Annual Demand for Peptide Therapeutics (in Kilograms)
Table 17.36. Demand Analysis: Annual Demand for Clinical Scale of Operation
Table 17.37. Demand Analysis: Annual Demand for Commercial Scale of Operation
Table 17.38. Demand Analysis: Annual Demand in North America
Table 17.39. Demand Analysis: Annual Demand in Europe
Table 17.40. Demand Analysis: Annual Demand in Asia Pacific
Table 17.41. Contract Peptide API Manufacturers: Installed Global Capacity
Table 17.42. Contract Peptide API Manufacturers: Distribution by Company Size
Table 17.43. Contract Peptide API Manufacturers: Distribution by Scale of Operation
Table 17.44. Contract Peptide API Manufacturers: Distribution by Location of Manufacturing Facility
Table 17.45. Overall Contract API Peptide Manufacturing Market, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.46. Contract Peptide API Manufacturing Market: Distribution by Scale of Operation, Conservative, Base, Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.47. Contract API Peptide Manufacturing Market: Distribution by Peptide Synthesis Methods Used, Conservative, Base, Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.48. Contract API Peptide Manufacturing Market: Distribution by Type of End User, Conservative, Base, Optimistic Scenarios, 2020-2030 (USD Million)
Table 17.49. Contract Peptide API Manufacturing Market: Distribution by Key Geographic Regions, 2020-2030 (USD Million)
Table 17.50. Contract API Peptide Manufacturing Market in North America, 2020, 2025 and 2030 (USD Million)
Table 17.51. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Small Companies (USD Million)
Table 17.52. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Mid-sized Companies (USD Million)
Table 17.53. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Large / Very Large Companies (USD Million)
Table 17.54. Contract API Peptide Manufacturing in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Table 17.55. Contract API Peptide Manufacturing Market in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Commercial Operations (USD Million)
Table 17.56. Contract API Peptide Manufacturing Market in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Chemical Synthesis Methods Used (USD Million)
Table 17.57. Contract API Peptide Manufacturing Market in North America, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Table 17.58. Contract API Peptide Manufacturing Market in Europe, 2020, 2025 and 2030 (USD Million)
Table 17.59. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Small Companies (USD Million)
Table 17.60. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Mid-sized Companies (USD Million)
Table 17.61. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Large / Very Large Companies (USD Million)
Table 17.62. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Table 17.63. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Commercial Operations (USD Million)
Table 17.64. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Table 17.65. Contract API Peptide Manufacturing Market in Europe, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)
Table 17.66. Contract API Peptide Manufacturing Market in Asia Pacific, 2020, 2025 and 2030 (USD Million)
Table 17.67. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Small Companies (USD Million)
Table 17.68. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Mid-sized Companies (USD Million)
Table 17.69. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Large / Very Large Companies (USD Million)
Table 17.70. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Preclinical / Clinical Operations (USD Million)
Table 17.71. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Commercial Operations (USD Million)
Table 17.72. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Chemical Synthesis Methods (USD Million)
Table 17.73. Contract API Peptide Manufacturing Market in Asia Pacific, Conservative, Base, Optimistic Scenarios, 2020-2030: Share of Non-Chemical Synthesis Methods (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. AAPPTec
  2. Abcepta
  3. Abclonal
  4. ABI Scientific
  5. Abzena
  6. ACES Pharma
  7. Active Peptide
  8. Activotec 
  9. Adar Biotech
  10. Advanced ChemTech
  11. Ajinomoto Bio-Pharma
  12. Alpha Diagnostic
  13. AltaBioscience
  14. AmbioPharm
  15. American Peptide
  16. Amunix 
  17. AnaSpec
  18. Antagene
  19. APL
  20. Arch Biopartners
  21. AstraZeneca
  22. Asymchem
  23. Atlantic Peptides
  24. Auspep
  25. Austin Chemical
  26. Baccinex 
  27. Bachem
  28. BCN Peptides
  29. Bio Basic
  30. Biopeptek Pharmaceuticals
  31. BioServUK
  32. Bio-Synthesis
  33. BioVectra
  34. Burrard Pharmaceuticals
  35. California Peptide Research
  36. Cambridge Peptides
  37. CanPeptide
  38. Cara Therapeutics
  39. CARBOGEN AMCIS
  40. CASLO 
  41. CBL (Chemical and Biopharmaceutical Laboratories)
  42. Celtek Peptides
  43. ChemPartner
  44. CHI Scientific
  45. Chiasma
  46. ChinaPeptides 
  47. Chinese Peptide
  48. CordenPharma
  49. Cosmo Bio 
  50. CPC Scientific
  51. Creative Peptides
  52. CSBio
  53. Dalton Pharma 
  54. Dr. Reddy's Custom Pharma Services 
  55. Eli Lilly 
  56. Enteris BioPharma
  57. EOC Pharma
  58. Europe Pharmaceuticals
  59. GenPro Biotech
  60. GenScript 
  61. GL Biochem
  62. GLyPharma Therapeutic
  63. GP Pharm
  64. Grey Matter Research Foundation
  65. HAMLET Pharma
  66. Hybio Pharmaceutical
  67. i-DNA Biotechnology 
  68. IDP Pharma
  69. Innovagen
  70. Institute Of Biomolecules Max Mousseron
  71. INTAVIS Bioanalytical Instruments 
  72. Iris Biotech
  73. Jitsubo
  74. Kaijie Peptide
  75. KareBayTM Biochem
  76. KeyBioscience
  77. Kinexus
  78. Lonza
  79. Lyotex
  80. Macrocyclics
  81. Mimotopes
  82. MuseChem 
  83. Neuland
  84. New England Peptide
  85. Novetide
  86. NUMAFERM 
  87. Ontores
  88. Oryn
  89. PEPDesign 
  90. Pepscan
  91. Peptide  International
  92. Peptide 2.0
  93. Peptide Institute
  94. Peptide Protein Research
  95. peptides&elephants
  96. Peptron
  97. Pfanstiehl
  98. PolyPeptide
  99. Primm Biotech
  100. Priveel peptides
  101. ProImmune
  102. Promore Pharma
  103. ProteoGenix 
  104. Provepharm
  105. Quantum Hi-Tech 
  106. RS Synthesis
  107. SBS Genetech
  108. Scancell 
  109. ScinoPharm 
  110. Sekisui XenoTech
  111. Selleck Chemicals
  112. Senn Chemicals
  113. Shenzhen JYMed Technology
  114. STA Pharmaceutical
  115. UNC Lineberger Comprehensive Cancer Center
  116. United BioSystems
  117. UPM Pharmaceuticals
  118. Wilshire Technologies
  119. Xaia Custom Peptides

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com